Table 3.

First line recommendations for patients who are not candidates for ICI combinations

Recommendations	Level of Evidence (LoE)	Grade of recommendation	Grade of consensus
In patients who are not candidates for check point inhibitor therapies, offer alternative treatment according to IMDC risk:
Favourable: bevacizumab + interferon, pazopanib, sunitinib or tivozanib	1+ +	A	Strong
Intermediate: cabozantinib, pazopanib, sunitinib or tivozanib	1+ + /1 −	B	Strong
Poor: cabozantinib or sunitinib	1+ /1 −	B	Consensus